Information Provided By: 
Fly News Breaks for July 9, 2019
NTLA
Jul 9, 2019 | 08:02 EDT
Baird analyst Madhu Kumar initiated Intellia Therapeutics with an Outperform rating and $23 price target. In a research note to investors, Kumar says he has early optimism that NTLA-2001, the company's transthyretin CIRSPR gene editing drug, has the potential to disrupt the treatment of hereditary TTR amyloidosis, or hATTR. Kumar thinks that a 2020 IND submission for NTLA-2001 could serve as a medium-term catalyst for Intellia shares.
News For NTLA From the Last 2 Days
NTLA
Apr 18, 2024 | 11:18 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here
